Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 09/30/2008. OMB 0651-0031
formation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | Application Number | | 10570229 | | |
|---|----------------------------|----|---------------|--|--|
| · · · · · · · · · · · · · · · · · · · | Filing Date | | 2006-02-28 | | |
| INFORMATION DISCLOSURE | First Named Inventor Bigga | | gadike et al. | | |
| STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Art Unit | · | 1624 | | |
| (NOt for submission under 37 CFR 1.99) | Examiner Name Berch | | ch, Mark L. | | |
| | Attorney Docket Numb | er | PB60476USw | | |

| | | | | _ | U.S.F | PATENTS | | | | | |
|----------------------|------------|---|-----------------------------|------------------------------------|---------------|---|---|---------|--|----|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue D | ate | Name of Patentee or Applicant of cited Document | | | Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear | | |
| | 1 | | | | | | | | · | | |
| If you wisl | h to ac | id additional U.S. Pater | nt citatio | n inform | ation pl | ease click the | Add button. | | | | |
| | | | U.S.P | ATENT | APPLIC | CATION PUB | ICATIONS | | | | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Fublication Code ¹ Date | | Name of Patentee or Applicant of cited Document | | | Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear | | |
| | 1 | | | | | | | | | | |
| If you wis | h to a | dd additional U.S. Publi | shed Ap | plication | citatio | n information p | olease click the Ad | d butto | in. | | |
| | | | | FOREIG | N PAT | ENT DOCUM | ENTS | | | | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² j | | Kind Code4 | Publication Date | Name of Patentee or Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear | T5 | |
| | 1 | 0325460 | EP | | | | (992.1 | 0 | | | |
| | 2 | 0434450 | EP | | | | 1999 - 0 | >> | | | |
| | 3 | 0628044 | EP | | | | 1994. | /2_ | | | |

/Mark Berch/ (02/25/2009)

| | | | | Application | on Number | | 10570229 | | |
|---|------------|---|----------|-------------|----------------|---------|---------------------------|----|---|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | | Filing Date | | | 2006-02-28 | | | | |
| | | First Named Inventor Bigga | | | adike et al. | | | | |
| | | | Art Unit | | | 1624 | | | |
| | | Examiner Name Berch | | | h, Mark L. | | | | |
| | | | | | Docket Num | ber | PB60476USw | | |
| | | | | | | | | | |
| | 4 | 0741710 | EP | | | | 1996-11 | | |
| | 5 | 95/21161 | wo | | | | 1995.08 | | |
| | 6 | 98/52949 | wo | | | | 1998-11 | | |
| - | 7 | 99/19327 | wo | | | | 1999 . 194 | | |
| | 8 | 00/19327 | wo | | | | 2600.04 | | |
| If you wis | h to a | Idd additional Foreign P | atent Do | cument cit | ation informat | ion ple | ease click the Add button | n | 1 |
| | | | | | LITERATUR | | | | |
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | Т5 | |
| | 1 | Berge et al., "Pharmaceutical Salts", J. of Pharm. Sci. Vol. 66(1), pp. 1-19, 1977 | | | | | | | |
| | 2 | Daluge et al., "An Efficient, Scalable synthesis of theh HIV Reverse Transcriptase Inhibitor Ziagen® (1592U89)", Nucleosides, Nucleotides & Nucleic Acids, Vol. 19, pp. 297-327, 2000 | | | | | | | |

/Mark Berch/ (02/25/2009)

Delivery Reviews, Vol 19, pp. 115-130, 1996

Activities", J. Heterocyclic Chem., Vol 38, pp. 299-303, 2001

3

Fleisher et al., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug

Legraverend et al., "Synthesis of a New Series of Purine Derivatives and their Anti-Cyclin-Dependent Kinase